IONTAS Collaboration With F-star Enters Oncology Phase 1 Clinical Trial

29 Jun 2021
www.biospace.com
Antibody
June 29, 2021 09:54 UTC CAMBRIDGE, England--(BUSINESS WIRE)-- IONTAS Limited (IONTAS), a leader in the discovery and optimization of fully human antibodies, today announces that F-star Therapeutics, Inc. (NASDAQ: FSTX), has dosed the first patients in a Phase 1 clinical trial, with FS222, a CD137/PD-L1 bispecific antibody. IONTAS applied its proprietary technology to generate a component utilized within FS222, which was subsequently licenced to F-star. The initiation of this trial adds to the growing portfolio of antibodies generated by IONTAS that are entering clinical trials. António Parada, CEO at IONTAS, commented: “We are delighted with the progress of this molecule, the platform offered by F-star taps into the growing number of bispecific antibodies entering the clinic and we are proud to be part of this movement. We wish F-star every success with the clinical trial and hope this can be the foundation of an effective cancer treatment.” View source version on businesswire.com: Contacts Zyme Communications Lorna Cuddon Tel: +44(0)7811 996 942 lorna.cuddon@zymecommunications.com Source: IONTAS Limited View this news release online at:
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.